ESC Congress coverages: The interventional cardiology perspective

Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.

The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...

Jonathan Curio provides his take on the MitrAI score study which was presented by Luigi Biasco at ESC Congress 2024 in London.

What was new and hot in interventional cardiology at #ESCCongress 2024!

Salvatore Brugaletta interviews Tiffany Patterson about the study design and results that she presented during the ESC Congress 2023 in Amsterdam.

The ARREST trial showed that in patients without STEMI, expedited transfer to a cardiac arrest centre after resuscitated OHCA was not associated with decreased 30-day mortality compared...

Cardiovascular disease in particular ischaemic heart disease is the leading cause of mortality worldwide. International guidelines provide recommendations on the best evidence-based care for patients. At the ESC Congress 2023 in Amsterdam, the ESC 2023 Guidelines on Acute Coronary Syndromes were presented and published1. Vijay Kunadian provides...

Nicola Ryan provides her take on the final results of OPT-BIRISK which were presented by Yaling Han during the ESC 2023 congress in Amsterdam.

Note the assumptions in this article are based on the presentation alone as the trial has not yet been published.

What was new and hot in interventional cardiology at #ESCCongress 2023!

These guidelines have been developed to support healthcare professionals with the diagnosis and management of patients with infective endocarditis.

Alex Sticchi interviews Victoria Delgado on the updated version which she presented during the ESC Congress 2023 in Amsterdam: Discover the key elements and take-home messages.

Luigi Biasco interviews Troels Højsgaard Jørgensen regarding the 10-year results of the NOTION trial which he presented at the ESC Congress 2023 in Amsterdam.

What can you learn about valve durability and life expectancy?

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...